Loading
A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Biosciences Japan GK, active and no longer recruiting.
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT04661007 by Incyte Biosciences Japan GK, with 72 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-07-01. Interventions recorded: tafasitamab, lenalidomide, parsaclisib, R-CHOP. Conditions listed: Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Monoclonal antibodies.
Shares Parsaclisib, Incyte.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Tafasitamab, Lenalidomide, Monoclonal antibodies, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/